JY231 injection for treating B-cell acute lymphoblastic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early-phase clinical trial evaluates the safety, tolerability, and initial efficacy of JY231 injection in patients diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). Participants will receive the JY231 treatment, and their responses will be monitored to assess the drug's effectiveness and safety profile. The study aims to gather preliminary data that could inform further development of this treatment option for B-ALL. The trial includes patients up to 75 years old who meet specific health criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. up to 75 years (Child, Adult) , either sex；
2. Bone marrow cell morphology examination showed the proportion of primitive and immature lymphocytes in the bone marrow is \>5%, or the bone marrow MRD analysis comfirmed as B-ALL.
3. Flow cytometry or histology confirmed positive expression of cluster of differentiation 19 (CD19);
4. According to the researcher's assessment, the expected survival period is greater than 3 months;
5. Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 3;
6. The patient has good liver, kidney, heart, and lung functions: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal(ULN), which can be relaxed to ≤ 5 × ULN for patients with liver invasion; Total serum bilirubin \< 34 μ Mol/L; Creatinine clearance rate\>30 mL/min; Cardiac ejection fraction (EF) ≥ 40%, without pericardial effusion and significant arrhythmia; Indoor oxygen saturation (SpO2) ≥ 92%;
7. Peripheral blood lymphocyte absolute count: absolute lymphocyte count (ALC) ≥ 0.5E9/L, blood platelet (PLT) \> 30E9/L, Hb \> 80g/L, with a single venous access and no other contraindications for blood cell separation;
8. MRI examination showed no active malignant cells in the cerebrospinal fluid, no brain metastases, or no central nervous system leukemia;
9. Individuals with fertility must agree to the use of efficient contraceptive methods;
10. The subject or their legal guardian can understand and voluntarily sign a written informed consent form.

Exclusion Criteria:

1. Pregnant or lactating women, as well as women with pregnancy plans within six months;
2. Virological tests of hepatitis B, hepatitis C, AIDS, syphilis and cytomegalovirus were positive;
3. Having a history of other tumors (excluding skin or cervical carcinoma in situ cured by root therapy and without evidence of disease activity);
4. Previously received treatment targeting CD19;
5. Received autologous hematopoietic stem cell transplantation within 6 weeks;
6. The presence of uncontrollable active bacterial or fungal infections;
7. Allergies to research related drugs or cellular components;
8. Active autoimmune diseases exist;
9. Patients with unstable or active ulcers or gastrointestinal bleeding currently present;
10. Individuals with mental or psychological disorders who cannot cooperate with treatment and efficacy evaluation;
11. Received other experimental drug treatments within the past 3 months;
12. Existence of grade II-IV acute graft versus-host disease (GVHD) or widespread chronic GVHD;
13. Researchers believe that other reasons are not suitable for clinical trial participants.

Where it's running

• 920th HJointLogistics
  Kunming, Yunnan, China Recruiting

Study contacts

• Principal investigator: Sanbin Wang — 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
• Study coordinator: Sanbin Wang, Doctor
• Email: sanbin1011@163.com
• Phone: 13187424131

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vaccine protection after blinatumomab in children with B-ALL

  This project will see if children and young adults (ages 1–21) with B-cell acute lymphoblastic leukemia who received blinatumomab keep protective immunity from routine childhood vaccines and whether revaccination restores immunity when levels are low.

  Recruiting at 2 sites Arkansas Children's Hospital Research Institute · Little Rock, Arkansas and 1 other locations · NCT07422337

• GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia

  This trial will test whether GT801 injections help adults with CD19-positive B-cell cancers (B-ALL, CLL, B-NHL) or autoimmune hemolytic anemia that have returned or not responded to prior treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Zhengzhou, Henan and 1 other locations · NCT07205315

• AZD4512 alone or with other cancer drugs for relapsed/refractory CD22-positive B‑cell ALL

  This trial will test whether AZD4512, given alone, is safe and can help adults and adolescents with relapsed or refractory CD22-positive B‑cell acute lymphoblastic leukemia.

  Recruiting at 21 sites Phase 1/2 AstraZeneca · Duarte, California and 26 other locations · NCT07109219

• Long-term health and quality of life after CD19 CAR T-cell therapy in B-ALL survivors

  This project will test whether standardized health checks can be done for children, adolescents, and young adults who are at least two years past CD19 CAR T-cell treatment for B-ALL.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07048535

• Newly diagnosed low‑risk pediatric B‑cell ALL treatment with short blinatumomab courses

  This protocol will try giving two short 14‑day courses of blinatumomab early and during consolidation for children with newly diagnosed low‑risk B‑cell ALL to allow less intensive later chemotherapy when deep MRD negativity is achieved.

  Recruiting Phase 2/3 Institute of Hematology & Blood Diseases Hospital, China · Hefei, Anhui and 26 other locations · NCT06882057

• Nutrition and exercise during hospital induction for adults with Philadelphia chromosome–negative B‑ALL

  This program will test whether guided nutrition and in-hospital exercise during induction therapy help adults with Philadelphia chromosome–negative B‑ALL keep muscle and limit excess body fat.

  Recruiting University of Chicago · Chicago, Illinois · NCT06785324

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.